相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1868
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Federal agencies acknowledged using keywords such as "health equity," "vaccine hesitancy," and "structural racism" to screen and terminate over 1,000 UC research grants worth nearly $2 billion. - The NIH alone suspended or cancelled more than 1,000 UC grants, including nearly 700 at UCLA, affecting vaccine research, cancer studies, and health disparities work. - Plaintiffs' lawyers argue the admissions prove First Amendment violations, unconstitutional geographic targeting, and illegal impoundment of Congressionally appropriated funds. - A court hearing on whether to skip trial and issue a final ruling restoring the grants is scheduled for October 20 before Judge Rita F. Lin.
- Proposition 38 would authorize $8.4 billion in state bonds for immunology and immunotherapy research, with half earmarked for cancer, heart disease, and Alzheimer's disease. - The measure would equally fund a UC-affiliated nonprofit research institute and a grant program for California public or nonprofit universities and institutions. - Supporters argue the bond is critical to offset NIH funding cuts that have disrupted clinical trials, with UC alone losing over $37 million in canceled federal grants. - Any treatments developed under the measure must be sold to Californians at 20% below the national average price, with 10% of licensing revenues returned to the state.
- A proposed $12 billion California Science and Health Research Bond Act (SB 895) missed the legislative deadline to qualify for the November 2026 ballot. - The bond aimed to counter federal research funding cuts by the Trump Administration, which has proposed approximately $32 billion in reductions to science agencies including the NSF. - UC Santa Barbara Chancellor Dennis Assanis warned that sustained federal funding losses undermine California's capacity in biomedical science, climate resilience, and public health. - A separate $8.4 million bond measure supporting Alzheimer's, cancer, and heart disease immunotherapy research did qualify for the ballot.
- A large multi-center study of over 1,500 patients across five University of California hospitals identified significant variations in neutropenia risk among commonly used antibody-drug conjugates (ADCs). - Gemtuzumab ozogamicin showed the highest risk of severe neutropenia with an odds ratio of 60.50, while fam-trastuzumab deruxtecan and ado-trastuzumab emtansine demonstrated significantly lower risks. - Patient-specific risk factors including pre-existing anemia, baseline liver dysfunction, immunodeficiency disorders, and breast malignancy were independently associated with increased neutropenia risk. - The findings provide crucial real-world evidence to guide personalized ADC therapy selection and monitoring strategies in clinical practice.
- Izotropic Corporation has confirmed regulatory alignment with the FDA for its IzoView Breast CT Imaging System following a pre-submission meeting in March 2025, clearing the path for a pivotal U.S. clinical trial. - The company has completed a comprehensive 150-page strategic business plan and sophisticated financial modeling to support commercialization efforts and is actively seeking financing for clinical execution. - Izotropic has revised its exclusive global licensing agreement with UC Davis to align with current strategic positioning and regulatory timelines, requiring achievement of U.S. regulatory approval by specified dates. - The company is conducting targeted investor outreach with high-net-worth individuals and institutional stakeholders to fund the full scope of its planned U.S. clinical study and market entry strategy.
- A U.S. appeals court has vacated a 2022 patent ruling, reopening the dispute over who first invented CRISPR gene editing in human cells between Nobel laureates Doudna/Charpentier and the Broad Institute's Feng Zhang. - The court determined that the Patent Trial and Appeal Board applied the wrong legal standard, stating inventors don't need to "know their invention would work" to get credit for conceiving it. - The decision could potentially redirect billions in licensing revenues and redefine patent law standards for invention conception, with implications extending beyond the 13-year CRISPR patent saga.
- The U.S. Court of Appeals for the Federal Circuit has partially vacated the Patent Trial and Appeal Board's previous decision in the CRISPR/Cas9 patent interference case, remanding it for further review. - Editas Medicine maintains confidence in its intellectual property portfolio, emphasizing that the decision does not affect existing licenses or its ability to license foundational CRISPR patents. - The company holds extensive patents covering CRISPR/Cas9 and CRISPR/Cas12a gene editing in human cells, with only a fraction involved in the ongoing interference proceedings.
- The Federal Circuit ruled that the Patent Trial and Appeal Board used flawed legal reasoning when evaluating the University of California's claims to CRISPR-Cas9 gene-editing technology in animal cells. - Nobel Prize-winning scientists from UC were incorrectly denied credit for conceiving the breakthrough CRISPR system that allows modification of animal cells, with the court finding the Board focused too heavily on "perceived experimental difficulties." - The case will return to the administrative tribunal for re-evaluation, potentially reshaping ownership rights to the revolutionary gene-editing technology that has significant implications for pharmaceutical research and development.
- Nearly 50% of patients with moderate to severe chronic hand eczema achieved a "deep response" with delgocitinib cream 20 mg/g by week 16, demonstrating significant relief from disease burden. - Approximately 25% of patients exhibited "consistent response" with sustained improvement in pain or itch scores, maintaining ≥75% improvement in disease severity throughout the treatment period. - One-third of patients who achieved complete clearance maintained their results even after stopping treatment, suggesting delgocitinib provides lasting therapeutic benefit beyond the application period.
- Research indicates that gut microbiome variability affects tamoxifen pharmacokinetics, potentially explaining the drug's limited efficacy in roughly 50% of breast cancer patients. - Specific gut bacteria, such as Bacteroides fragilis, produce enzymes like β-glucuronidase, which recycle tamoxifen back into the bloodstream, enhancing its effectiveness. - The study suggests stool tests could predict patient responsiveness to tamoxifen, allowing for individualized therapeutic strategies and improved clinical outcomes. - Dietary interventions to support beneficial gut bacteria growth may offer a holistic approach to enhance tamoxifen's efficacy in breast cancer treatment.
